LONZA GRP AG/ADR (OTCMKTS:LZAGY) – Stock analysts at Jefferies Financial Group reduced their FY2019 earnings per share (EPS) estimates for LONZA GRP AG/ADR in a research report issued on Thursday, March 14th. Jefferies Financial Group analyst P. Welford now forecasts that the company will earn $1.24 per share for the year, down from their previous forecast of $1.27. Jefferies Financial Group also issued estimates for LONZA GRP AG/ADR’s FY2020 earnings at $1.41 EPS, FY2021 earnings at $1.63 EPS, FY2022 earnings at $1.86 EPS and FY2023 earnings at $2.07 EPS.
A number of other research firms have also weighed in on LZAGY. Zacks Investment Research lowered shares of LONZA GRP AG/ADR from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Bank of America lowered shares of LONZA GRP AG/ADR from a “buy” rating to a “neutral” rating in a research note on Thursday, January 31st. Finally, ValuEngine lowered shares of LONZA GRP AG/ADR from a “buy” rating to a “hold” rating in a research report on Wednesday, December 5th.
LONZA GRP AG/ADR Company Profile
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. Its products and services cover bio research solutions, such as stem cells primary cells and media, cell culture, transfection, exosomes, and assay solutions; electrophoresis of nucleic acids and proteins; primary and stem cell protocols; Hepatocytes/ADMETox solutions for microsomes and primary cell culture applications; and CytoSMART system, a live cell imaging and monitoring system.
See Also: Fiduciary
Receive News & Ratings for LONZA GRP AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LONZA GRP AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.